Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

Oral butyrate prodrug in preclinical testing at Vertex

Dec. 13, 1996

DuPont Merck evaluates new candidate cognition enhancer

Dec. 13, 1996

DuPont Merck reports pharmacokinetic data for novel gpIIb/IIIa antagonist

Dec. 13, 1996

New ET antagonist in preclinical testing at Parke-Davis

Dec. 13, 1996

New HIV-1 protease inhibitor in development at LG Chemical

Dec. 13, 1996

Glaxo Wellcome evaluates new alpha1a-adrenoceptor antagonist

Dec. 13, 1996

Japanese academic researchers isolate new quassinoid compound

Dec. 10, 1996

Merck & Co. describes lipid A biosynthesis inhibitor with antibacterial activity

Dec. 2, 1996

New anxiolytic under development at Parke-Davis

Dec. 2, 1996

Antiepileptic agent reported by Parke-Davis

Dec. 2, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...